Daniel K. Nomura
Associate Professor of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology
About Daniel K. Nomura
Dan Nomura is an associate professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an associate adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology at UC Berkeley with Professor John Casida and was a postdoctoral fellow at The Scripps Research Institute with Professor Ben Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, and the Department of Defense Breakthroughs Award. The Nomura Research Group is focused on mapping drivers of human disease through the development and application of chemical biology approaches including chemoproteomic and metabolomic platforms.
The Nomura Research Group is focused on redefining druggability using chemoproteomic platforms to innovative transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or “druggable hotspots” that small-molecules can bind to modulate protein function. Our research group addresses this challenge by developing chemoproteomic platforms to discover and pharmacologically target unique and novel druggable hotspots for disease therapy. We currently have four major research directions. Our first major focus is on developing chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel druggable hotspots for undruggable protein targets and incurable diseases. Our second research area focuses on covalent ligand discovery against druggable hotspots targeted by therapeutic natural products using chemoproteomic platforms to discover new therapeutic targets and synthetically tractable therapies for complex human diseases. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to expand the scope of targeted protein degradation to target and degrade undruggable proteins. Our fourth research area focuses on using chemoproteomic platforms to map on and off-targets of environmental and pharmaceutical chemicals towards discovering new toxicological mechanisms. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.
For more information, visit The Nomura Research Group
Chemoproteomics-enabled covalent ligand discovery to drug the undruggable proteome
One of the biggest challenges in curing human diseases is that most, 90 %, of the proteome is considered “undruggable”—most proteins are devoid of known functional binding pockets or “druggable hotspots” that drugs can bind to modulate their functions for disease therapy. Developing new approaches to both discover binding pockets or “druggable hotspots” and to pharmacologically target these sites with small-molecules will radically expand our scope of the druggable proteome and lead to new disease cures. Multiple technologies have arisen to tackle the undruggable proteome. One major strategy is a chemoproteomic platform termed isotopic tandem orthogonal proteolysis-enabled activity-based protein profiling (isoTOP-ABPP) that uses reactivity-based chemical probes to map proteome-wide reactive, functional, and druggable hotspots directly in complex proteomes. When used in a competitive manner, covalent ligands can be competed against reactivity-based probe binding to druggable hotspots to pharmacologically target undruggable proteins. Collectively, we have identified >100,000 potential ligandable binding pockets across >20,000 proteins suggesting that we can develop small-molecule modulators against not just 10 % but rather the majority of the proteome. A major focus of our lab is to couple the phenotypic or biochemical screening of our covalent ligand libraries with our chemoproteomic platforms to rapidly discover therapeutic small-molecule leads and druggable hotspots against undruggable protein targets and incurable diseases.
Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products using chemoproteomic platforms
Natural products isolated from microbes, plants, and other living organisms have been a tremendous source of cancer therapeutics and comprise about 50 % of the drugs that are used for cancer chemotherapy. While there are countless additional natural products that have been shown to have anti-cancer activities, there are major bottlenecks associated with developing natural products as drugs. First, many of these drugs have been difficult to isolate in large quantities from their biological sources and have been challenging to synthesize. Second, the direct targets and mechanisms of action of most anti-cancer natural products remain poorly understood. Among these natural products are agents that contain potential reactive electrophilic centers that can covalently react with nucleophilic amino acid hotspots on proteins to modulate their biological action. We believe that identifying the direct targets and mechanisms of anti-cancer natural products would not only enable the discovery of unique druggable hotspots that can be targeted for cancer therapy, but also enable pharmacological interrogation of these targets using covalent ligand discovery approaches to uncover more synthetically accessible leads for cancer therapy. Our lab has been using isoTOP-ABPP chemoproteomic platforms to map druggable hotspots targeted by covalently-acting anti-cancer natural products to discover new cancer therapy targets. We have then been interrogating these sites with libraries of covalent ligands to generate more synthetically tractable lead compounds that target the same sites.
Expanding the scope of the degradable proteome using chemoproteomic platforms
Another groundbreaking technology enabling drug discovery efforts against undruggable targets is termed targeted protein degradation that exploits cellular protein degradation machinery to selectively eliminate target proteins. Targeted protein degradation involves the utilization of bifunctional molecules called “degraders” with one end consisting of a small-molecule ligand that binds to the protein of interest linked to another end consisting of an E3 ligase recruiting small-molecule binding to an E3 ligase which in-turn ubiquitinates and proteosomally degrades the target. The promise of this strategy is that targeted protein degradation can be potentially used to target and degrade any protein target in the proteome, including the undruggable proteome. However, two major challenges exist in the application of this technology. First, undruggable targets by definition are likely not to possess ligands that bind to them. Second, while there are >500 different E3 ligases, there are only a few E3 ligase recruiters. To overcome the first challenge, our research group couples chemoproteomics-enabled covalent ligand discovery platforms with targeted protein degradation technologies to pharmacologically target and proteosomally degrade undruggable protein targets. To overcome the second challenge, our group has also been using chemoproteomics-enabled covalent ligand screening approaches to develop an arsenal of new E3 ligase recruiters that can be coupled to linkers and protein-targeting ligands to enable degradation of protein targets.
Developing safer environmental and pharmaceutical chemicals using chemoproteomic platforms
We are environmentally exposed to countless synthetic chemicals on a daily basis, with an increasing number of these chemical exposures linked to adverse health effects. However, our understanding of the (patho)physiological effects of these chemicals remains poorly understood, due in part to a general lack of effort to systematically and comprehensively identify the direct interactions of environmental chemicals with biological macromolecules in mammalian systems in vivo. Understanding the direct protein targets of chemicals provides critical information on the types of biochemical and (patho)physiological effects that may be expected from exposure to the chemical. Our lab has been using chemoproteomic strategies to comprehensively identify chemical-protein interactions in complex biological systems, which has in-turn allowed us to identify unique and novel toxicological mechanisms for many widely used chemicals in our environment.
Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK. (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chemical Biology 23, 1-12.
Counihan JC, Ford B, Nomura DK. (2016) Mapping Proteome-Wide Interactions of Reactive
Chemicals using Chemoproteomic Platforms. Current Opinions in Chemical Biology 30, 68-
Medina-Cleghorn D, Bateman LA, Ford B, Heslin A, Fisher KJ, Dalvie ED, Nomura DK.
(2015) Mapping proteome-wide targets of environmental chemicals using reactivity-based
chemoproteomic platforms. Chemistry and Biology 22, 1394-1405. PMID26496688
Piano V#, Benjamin DI#, Valente S, Nenci S, Mai A, Aliverti A, Nomura DK*, Mattevi A*.
(2015) Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer
agents. ACS Chemical Biology doi: 10.1021/acschembio.5b00466. PMID 26322624 (#co-first
authors; * co-corresponding authors).
Queiroz A, Medina-Cleghorn D, Marjanovic O, Nomura DK, Riley LW. (2015) Comparative
metabolic profiling of Mycobacterium tuberculosis: cell wall lipid reorganization as a
virulence factor. Pathogens and Disease pii: ftv066. PMID26319139.
Sanchez-Alavez M, Nguyen W, Mori S, Moroncini G, Viader A, Nomura DK, Cravatt BF,
Conti B. (2015) Monoacylglycerol lipase regulates fever response. Plos One 10, e0134437.
Kohnz RA, Mulvihill MM, Chang JW, Hsu K-L, Sorrentino A, Cravatt BF, Bandyopadhyay S,
Goga A, Nomura DK. (2015) Activity-based protein profiling of oncogene-driven changes in
metabolism reveals PAFAH1B2 and 1B3 as broad-spectrum cancer therapy targets. ACS
Chemical Biology 10, 1624-1630. PMID: 25945974.
Benjamin DI, Li DS, Lowe, W, Heuer T, Kemble G, Nomura DK. (2015) Diacylglycerol
metabolism and signaling is a predictive and driving force underlying FASN inhibitor
sensitivity in cancer cells. ACS Chemical Biology 10, 1616-1623. PMID: 25871544
Rashidian J, Le Scolan E, Ji X, Mulvihill MM, Nomura DK, Luo K. (2015) Ski regulates
Hippo and TAZ signaling to suppress breast cancer progression. Science Signaling 10,
ra14. PMID: 25670202
Anderson CM, Kazantzis M, Wang J, Venkatraman S, Goncalves RLS, Quinlan CL, Ng R,
Jastroch, M, Benjamin DI, Nie B, Herber C, Van A-AN, Park MK, Yun D, Chan K, Yu A,
Vuong P, Febbraio M, Nomura DK, Napoli JL, Brand MD, Stahl A. (2015) Dependence of
brown adipose tissue function on CD36-mediated coenzyme Q uptake. Cell Reports 10,
505-515. PMID 25620701
Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP,
Southern M, Scampavia L, Fernandez-Vega V, Dix MM, Cameron MD, Hodder PS, Rosen
H, Nomura DK, Kwon O, Hsu K-L, Cravatt BF. (2015) A selective inhibitor of platelet-
activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. ACS
Chemical Biology 10, 925-932. PMID: 25602368
Lysenko LV, Kim J, Henry C, Tyrtyshnaia A, Kohnz RA, Madamba F, Simon GM,
Kleschevnikova NE, Nomura DK, Ezekowitz RAB, Kleschevnikov AM. (2014)
Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in aged
Ts65Dn mice, a model of Down Syndrome. Plos One 9, e114521. PMID: 25474204.
Valdearcos M, Robblee M, Benjamin DI, Nomura DK, Xu AW, Koliwad SK. (2014) Microglia
Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and
Neuronal Function. Cell Reports 9, 1-15. PMID: 25497089
Hunerdosse D, Morris PJ, Miyamoto DK, Fisher KJ, Bateman LA, Ghazaleh J, Zhong S,
Nomura DK. (2014) Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-
Lowering Target. ACS Chemical Biology. Doi: 10.1021/cb500717g. PMID: 25343321.
Medina-Cleghorn D, Nomura DK. (2014) Exploring metabolic pathways and regulation
through functional chemoproteomic and metabolomic platforms. Chemistry & Biology 21,
1171-1184. PMID: 25237861.
Cai X, Perttula K, Pajouh SK, Hubbard A, Nomura DK, Rappaport SM. (2014) Untargeted
lipidomic profiling of human plasma reveals differences due to race, gender, and smoking
status. Metabolomics: Open Access 4, 1000131.
Mulvihill MM, Nomura DK. (2014) Metabolomic Strategies to Map Functions of Metabolic
Pathways. AJP Metabolism and Endocrinology 307, E237-E244. PMID: 24918200
Latimer LN, Lee MR, Medina-Cleghorn D, Kohnz RA, Nomura DK, Dueber JE. (2014)
Employing a combinatorial expression approach to characterize xylose utilization in
Saccharomyces cerevisiae. Metabolic Engineering 25, 20-29. PMID: 24930894.
Mulvihill MM, Benjamin DI, LeScolan E, Ji X, Shieh A, Green M, Narasimhalu T, Morris PJ,
Luo K, Nomura DK. (2014) Metabolic Profiling Reveals PAFAH1B3 as a critical driver of
breast cancer pathogenicity. Chemistry & Biology 21, 831-840. PMID: 24954006
Benjamin DI, Louie S, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A,
Bandhyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng-SW, Nomura DK. (2014) INPP1
Promotes Cancer Aggressiveness by Linking Inositol Phosphate Recycling to Glycolytic and
Lipid Metabolism. ACS Chemical Biology 20, 1340-1350. PMID: 24738946
Kohnz RK, Nomura DK. (2014) Chemical approaches to therapeutically target the
metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. Chemical Society
Reviews 43, 6859-6869. PMID: 24676249
Morris PJ*, Medina-Cleghorn D*, Heslin A, King S, Orr J, Krauss RM, Nomura DK. (2014)
Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause
serum hypertriglyceridemia. ACS Chemical Biology 9, 1097-1103. (*authors contributed
equally to the work) PMID: 24597639
Hunerdosse D, Nomura DK. (2014) Activity-based proteomic and metabolomic approaches
for understanding metabolism. Current Opinion in Biotechnology 28C, 116-126. PMID
Poole D, Lee M, Tso P, Bunnett N, Yo S, Lieu T, Shiu A, Wang J-C, Nomura DK, and
Aponte GW. (2014) Feeding dependent activation of enteric cells and sensory neurons by
lymphatic fluid: evidence for a neurolymphocrine system. AJP-Gastrointestinal and Liver
Physiology 306, G686-G698. PMID: 24578341
Dominguez E, Galmozzi A, Chang JW, Hsu K-L, Pawlak J, Li W, Godio C, Thomas J,
Partida D, Niessen S, O’Brien PE, Russell AP, Watt MJ, Nomura DK, Cravatt BF, Saez E.
(2014) Integrated phenotypic screening and activity-based proteomics defines a role for
carboxylesterase 3 in obesity and diabetes. Nature Chemical Biology 10, 113-121. PMID:
Medina-Cleghorn D, Heslin A, Morris PJ, Mulvihill MM, Nomura DK. (2014)
Multidimensional profiling platforms reveal metabolic dysregulation caused by
organophosphorus pesticides. ACS Chemical Biology 9, 423-432. PMID: 24205821
Nomura DK, Cravatt BF. (2013) Lipid Metabolism in Cancer. Biochimica et Biophysica
Acta—Molecular and Cell Biology of Lipids 1831, 1497-1498. PMID: 23921253
Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Luo K, Nomura DK. (2013) The ether
lipid generating enzyme AGPS alters the balance of structural and signaling lipids that fuel
cancer pathogenicity. Proceedings of the National Academy of Sciences, USA 110, 14912-
14917. PMID: 23980144
Louie SM*, Roberts LS*, Mulvihill MM, Luo K, Nomura DK. (2013) Cancer cells incorporate
and remodel exogenous fatty acids into structural and oncogenic signaling lipids. Biochimica
et Biophysica Acta—Molecular and Cell Biology of Lipids 1831, 1566-1572. PMID:
23872477 (* authors contributed equally to the work)
Louie SM, Roberts LS, Nomura DK. (2013) Mechanisms linking obesity and cancer.
Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids 1831, 1499-1508.
Medina-Cleghorn D, Nomura DK. (2013) Chemical Approaches to Study Metabolic
Networks. Pflugers Archive 465,427-440. PMID: 23296751
Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, Holovac E, Hasko G, Cravatt
BF, Nomura DK#, Pal Pacher#. (2013) Monoacylglycerol lipase controls endocannabinoid
and eicosanoid signaling and hepatic injury in mice. Gastroenterology 144, 808-817. PMID:
23295443 (# co-corresponding authors)
Mulvihill MM, Nomura DK. (2013) Therapeutic Potential of Monoacylglycerol Lipase
Inhibitors. Life Sciences 92, 492-497. PMID: 23142242
Morrison BE, Garibaldi Marcondes MC, Nomura DK, Sanchez-Alavez M, Saar I, Bartfai T,
Maher P, Sugama S, Conti B. (2012) IL-13Ralpha1 expression in dopaminergic neurons
contributes to their oxidative stress-mediates loss following chronic systemic treatment with
LPS. Journal of Immunology 189, 5498-5502. PMID: 23169588
Benjamin DI, Cravatt BF, Nomura DK. (2012) Global Profiling Strategies towards Mapping
Dysregulated Metabolic Pathways in Cancer. Cell Metabolism 16, 565-567. PMID:
Piro JR, Benjamin DI, Duerr JM, Pi YQ, Gonzales C, Schwartz JW, Nomura DK#, Samad
TA#. (2012) A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis
in a Mouse Model of Alzheimer's Disease. Cell Reports 1, 617-623. PMID: 22813736 (# co-
Nomura DK#, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM,
Hahn YK, Lichtman AH, Conti B, Cravatt BF#. (2011) Endocannabinoid hydrolysis generates
brain eicosanoids that promote neuroinflammation. Science 334, 809-813. PMID: 22021672
(# co-corresponding author)
Ruby MA, Nomura DK, Hudak CSS, Barber A, Casida JE, Krauss RM. (2011) Overactive
endocannabinoid signaling induces hepatic steatosis, insulin resistance, and global
transcriptional changes. Plos One 6, e26415. PMID: 22073164
Nomura DK#, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt
BF#. (2011) Monoacylglycerol lipase exerts bidirectional control over endocannabinoid and
fatty acid pathways to support prostate cancer pathogenesis. Chemistry & Biology 18, 848-
856. PMID: 21802006 (# co-corresponding author)
Ramesh D, Ross GR, Schlosburg JE, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-
Selley LJ, Cravatt BF. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates
precipitated withdrawal symptoms in mice. Journal of Pharmacology and Experimental
Therapeutics 339, 173-185. PMID: 21719468
Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. (2011) Inhibition of
monoacylglycerol lipase (MAGL) attenuates NSAID-induced gastric hemorrhages in mice.
Journal of Pharmacology and Experimental Therapeutics 338, 795-802. PMID: 21659471
Chang JW, Nomura DK, Cravatt BF. (2011) A potent and selective inhibitor of
KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chemistry & Biology 18,
476-484. PMID: 21513884
Ahn K, Smith SE, Liimata MB, Sadagopan N, Dudley D, Young T, Wren P, Zhang Y,
Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stif C,
Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. (2011) Mechanistic and
pharmacological characterization of PF-04457845: a highly potent and selective FAAH
inhibitor that reduces inflammatory and noninflammatory pain. Journal of Pharmacology and
Experimental Therapeutics 338, 114-124. PMID: 21505060
Nomura DK#, Casida JE#. (2011) Activity-based protein profiling of organophosphorus and
thiocarbamate pesticides reveals multiple secondary targets in the mammalian nervous
system. Journal of Agricultural and Food Chemistry 59, 2808-2815. PMID: 21341672 (# co-
Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu R, Nomura DK, Cravatt BF, Cubitt B, de la
Torre JC, Hessell AJ, Burton DR. (2011) Design, synthesis and biological evaluation of a
biyouyanagin compound library. Proceedings of the National Academy of Sciences, USA
108, 6715-6720. PMID: 21245351
Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V,
Chase P, Hodder PS, Schűrer, Nomura DK, Rosen H, Fu GC, Cravatt BF. (2011) Academic
cross-fertilization by public screening yields a remarkable class of protein phosphatase
methylesterase-1 inhibitors. Proceedings of the National Academy of Sciences, USA 108,
6811-6816. PMID: 21398589
Kopp F, Komatsu T, Nomura DK, Trauger SA, Thomas JR, Simon GM, Cravatt BF. (2010)
The glycerophospho-metabolome and its influence on amino acid homeostasis by brain
metabolomics of GDE1(-/-) mice. Chemistry & Biology 17, 831-840. PMID: 20797612
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Nguyen PT, Ramesh D, Kinsey SG,
Booker L, Burston JK, Wise LE, Ghosh S, Selley DE, Sim-Selley LJ, Liu Q, Cravatt BF,
Lichtman AH. (2010) Sustained inactivation of monoacylglycerol lipase produces functional
antagonism of the brain endocannabinoid system. Nature Neuroscience 13, 1113-1119.
Nomura DK, Dix MM, Cravatt BF. (2010) Chemoproteomic Approaches for Biochemical
Pathway Discovery in Cancer. Nature Reviews Cancer 10, 630-638. PMID: 20703252
Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. (2010)
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis.
Cell 140, 49-61. PMID: 20079333
Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ,
Lichtman AH, Wiley JL, Cravatt BF. (2009) Dual blockade of FAAH and MAGL identifies
behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the
National Academy of Sciences, USA 106, 20270-20275. PMID: 19918051
Long JZ, Nomura DK, Cravatt BF. (2009) Mechanistic characterization of selective
monoacylglycerol lipase inhibition reveals differences in central and peripheral
endocannabinoid metabolism. Chemistry & Biology 16, 744-753. PMID: 19635411
Ruby M*, Nomura DK*, Hudak CS, Mangravite LM, Chiu S, Casida JE, Krauss RM. (2008)
Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of
triglyceride-rich lipoproteins. Proceedings of the National Academy of Sciences, USA 105,
14561-14566. PMID: 18794527 (* co-first author)
Nomura DK, Ward AM, Hudak CS, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL,
Lichtman A, Casida JE. (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol
action and arachidonic acid levels. Bioorganic Medicinal Chemistry Letters 18, 5875-5878.
Casida JE, Nomura DK, Vose SC, Fujioka K. (2008) Organophosphate-Sensitive Lipases
Modulate Brain Lysophospholipids, Ether Lipids and Endocannabinoids. Chemico-Biological
Interactions 175, 355-64. PMID: 18495101
Nomura DK, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida
JE. (2008) Activation of the endocannabinoid system by organophosphorus nerve agents.
Nature Chemical Biology 4, 373-378. PMID: 18438404
Nomura DK, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Dual Roles of
Brain Serine Hydrolase KIAA1363 in Ether Lipid Metabolism and Organophosphate
Detoxification. Toxicology and Applied Pharmacology 228, 42-482. PMID: 18154358
Nomura DK, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Serine
Hydrolase KIAA1363: Toxicological and Structural Features with Emphasis on
Organophosphate Interactions. Chemical Research in Toxicology 19, 1142-1150. PMID:
Quistad GB, Liang SN, Fisher KJ, Nomura DK, Casida JE. (2006) Each Lipase has a
Unique Sensitivity Profile for Organophosphorus Inhibitors. Toxicological Sciences 91,166-
172. PMID: 16449251
Nomura DK, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain
Detoxifying Enzyme for Organophosphorus Nerve Poisons. Proceedings of the National
Academy of Sciences, USA 102, 6195-6200. PMID: 15840715
Segall Y, Quistad GB, Sparks SE, Nomura DK, Casida JE. (2003) Toxicological and
Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor
Ligands. Toxicological Sciences 76, 131-137. PMID: 12944568
Segall Y, Quistad GB, Nomura DK, Casida JE. (2003) Arachidonylsulfonyl Derivatives as
Cannabinoid CB1 Receptor and Fatty Acid Amide Hydrolase Inhibitors. Bioorganic Medicinal
Chemistry Letters 13,3301-3303. PMID: 12951114
Quistad GB, Nomura DK, Sparks SE, Segall Y, Casida JE. (2002) Cannabinoid CB1
Receptor as a Target for Chlorpyrifos Oxon and Organophosphorus Pesticides. Toxicology
Letters 135, 89-93. PMID: 12243867
Quistad GB, Sparks SE, Segall Y, Nomura DK, Casida JE. (2002) Selective Inhibitors of
Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and
Acetylcholinesterase: Toxicological Implications. Toxicology and Applied Pharmacology 179,
57-63. PMID: 11884237
Saghatelian A, Nomura DK, Weerapana E (2016) Omics: The maturation of chemical biology. Current Opinions in Chemical Biology 30: v-vi. PMID 26739665
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. (2016) Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine Doi: 10.1038/nm.4055. PMID 26950360
Nikkanen J, Forsstrom S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov D, Viinamaki J, Roivainen A, Marjamaki P, Liljenback H, Ahola S, Buzkova J, Terzioglu M, Khan NA, Pirnes-Karhu S, Paetau A, Lonnqvist T, Sajantila A, Isohanni P, Tyynaismaa H, Nomura DK, Battersby B, Velagapudi V, Carroll CJ, Suomalainen A (2016) Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metabolism. Feb 23. pii: S1550-4131(16)30012-2. doi: 10.1016/j.cmet.2016.01.019. PMID 26924217
Zhang J, Medina-Cleghorn D, Bernal-Mizrachi L, Bracci PM, Hubbard A, Conde L, Riby J, Nomura DK, Skibola C (2016) The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience 3, 31-41.
Nomura DK, Casida JE (2016) Lipases and their inhibitors in health and disease. Chemico-Biological Interactions doi: 10.1016/j.cbi.2016.04.004. PMID 27067293.
Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, Lou J, Rao RR, Chang MT, Jedrychowski MP, Paolo J, Griffin PR, Nomura DK*, Spiegelman BM* (2016) PM20D1 secretion by thermogenic adipose cells regulates lipidated amino acid uncouplers of mitochondrial respiration. Cell 166, 424-435. PMID 27374330 (*co-corresponding authorship)
Kohnz RA, Roberts, LS, DeTomaso D, Badyopadhyay S, Yosef N, Nomura DK. (2016) Protein sialylation regulates a gene expression signature that promotes breast cancer cell pathogenicity. ACS Chemical Biology doi: 10.1021/acschembio.6b00433. PMID 27380425
Braverman J, Sogi KM, Benjamin D, Nomura DK, Stanley SA. (2016) HIF-1alpha is an essential mediator of IFA-gamma-dependent immunity to Mycobacterium tuberculosis. Journal of Immunology doi: 10.4049/jimmunol.1600266. PMID 27430718
Sogi K, Holsclaw C, Fragiadakis G, Nomura DK, Leary J, Bertozzi C. (2016) Biosynthesis and regulation of sulfomenaquinone, a metabolite associated with virulence in Mycobacterium tuberculosis. ACS Infectious Diseases DOI: 10.1021/acsinfecdis.6b00106.